Episode Summary

Out of all the dozens of types of cancer that occur in humans, we habitually screen for only five: breast, cervical, colon, prostate, and lung. But what if there were a single test that could detect 50 types of cancer, based on a simple blood draw? That's exactly what's possible today, thanks to the Galleri test, introduced by Grail in 2021. The $949 test, which won breakthrough designation from the FDA in 2019, uses machine learning to assess the patterns of methyl groups—molecules that attach to chromosomes and control gene activity—in free-floating DNA shed by tumors. This week Harry interviews Grail's president, Dr. Josh Ofman, who says that if multi-cancer early detection tests like Galleri are eventually approved for population-level screening, it could help avert 100,000 deaths per year.


The content above was previously recorded. The views herein were made at the time of this recording and are not updated to reflect changes in economic or financial circumstances. The opinions are those of the contributor and not Scientia Ventures, LLC, its affiliates, officers, or employees. Nothing herein constitutes a recommendation, solicitation, or offer to purchase securities or private funds, which can only be made through the relevant offering documents.